Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.30 looking for a slap here. let's get movin!
they have a great scientific advisory board as well as a great business board...time to move up!
he dont have any..
huge stuff langlui..going to see a lot more good news coming our way...once they get on the BB, i see that private equity closing!
i love how open SPPH is with its shareholders...now becoming a reporting company will make them even MORE open and transparent !
I'm sure one condition of the private equity placement is that they become fully reporting....they are on their way to that equity placement!
great news today! awesome stuff...uplisting!
SPPH UPLISTING TO OTCBB
http://finance.yahoo.com/news/Spencer-Pharmaceutical-Begins-iw-727536723.html?x=0&.v=1
SPPH NEWS!
Spencer Pharmaceutical Begins Process for OTCBB Listing
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.29 0.00
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Wednesday November 3, 2010, 8:00 am EDT
BOSTON, MA--(Marketwire - 11/03/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has begun the process to upgrade its listing to the OTCBB.
According to the company, it is imperative in today's economy to be fully reporting to provide shareholders with maximum transparency.
"Management's objectives are focused on developing a responsible and cohesive strategy to develop and roll out our drug delivery system as shown with the recent addition of Dr. Lachance, who will be spearheading our Regulatory Affairs goals and objectives," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition, "The board of directors at its most recent meeting moved to begin the process to upgrade its listing to the OTCBB. Naturally, every move, be it to the NASDAQ or above, begins with this first step to start the process. We are building a team that is committed in developing a sustainable business for our shareholders," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
SPPH NEWS!
Spencer Pharmaceutical Begins Process for OTCBB Listing
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.29 0.00
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Wednesday November 3, 2010, 8:00 am EDT
BOSTON, MA--(Marketwire - 11/03/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has begun the process to upgrade its listing to the OTCBB.
According to the company, it is imperative in today's economy to be fully reporting to provide shareholders with maximum transparency.
"Management's objectives are focused on developing a responsible and cohesive strategy to develop and roll out our drug delivery system as shown with the recent addition of Dr. Lachance, who will be spearheading our Regulatory Affairs goals and objectives," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition, "The board of directors at its most recent meeting moved to begin the process to upgrade its listing to the OTCBB. Naturally, every move, be it to the NASDAQ or above, begins with this first step to start the process. We are building a team that is committed in developing a sustainable business for our shareholders," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
only way OS is growing is to make room for private funding per today's PR
or you too stoned from prop 19 in cali? JK!
is there ANYTHING significant going on here?
SPPH up 13% from today's low...this thing moves on air! super low float! huge news out today!
let's go boys and girls...last 16 minutes of the day...let's see some .30s!
great 200k volume this far..let's keep it up for the next 40 minutes
SPPH making a move from today's lows...you gotta check out the two PRS from today!!!
http://finance.yahoo.com/q?s=SPPH.PK
SPPH making a move from today's lows...you gotta check out the two PRS from today!!!
http://finance.yahoo.com/q?s=SPPH.PK
SPPH putting out great PRs this entire past month! everyone should radar ASAP!
also will give the company some extra money for more research!
a move past .30 would be prime for the rest of the week IMO
time to tighten this spread within .01 and get moving past .30
SPPH nice 140k volume so far...suppppper low float here!
so much info to go over. only more to come! i see some major PRs coming out in the next few days!
looks like the upturn has started again...like i have been saying all along, this company has been putting out great PR after great PR...so much good info coming down the pipes!
definitely see a big time transaction coming down the line...we should be getting more and more news regarding this IMO!
private equity looking to invest here! big money coming in! i love it!
solid volume this first first two hour span
SPPH is lookinggggg good! time for a massive move to greener grasses
MORE SPPH NEWS
Spencer Pharmaceutical Receives Letter of Interest
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.30 +0.02
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Tuesday November 2, 2010, 10:00 am EDT
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that the company has received a letter of interest by a private equity fund for a proposed important investment in the shares of the company.
According to the letter of interest, the private equity fund has requested its identity be kept confidential until further discussion and due-diligence is undertaken. However, no price has yet to be discussed nor any formal offer made.
"Although it is very flattering to be courted at this early stage, our objectives are clear and we will continue to work with our partners in licensing our technology for the Met4 as well as our extended release Ibuprofen," said Dr. Arella, President of Spencer Pharmaceutical Inc. "Naturally, if a formal offer was to be made by the private equity fund, the board of directors would consider, evaluate and recommend a course of action to its shareholders," further added Dr. Arella.
The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
MORE SPPH NEWS
Spencer Pharmaceutical Receives Letter of Interest
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.30 +0.02
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Tuesday November 2, 2010, 10:00 am EDT
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that the company has received a letter of interest by a private equity fund for a proposed important investment in the shares of the company.
According to the letter of interest, the private equity fund has requested its identity be kept confidential until further discussion and due-diligence is undertaken. However, no price has yet to be discussed nor any formal offer made.
"Although it is very flattering to be courted at this early stage, our objectives are clear and we will continue to work with our partners in licensing our technology for the Met4 as well as our extended release Ibuprofen," said Dr. Arella, President of Spencer Pharmaceutical Inc. "Naturally, if a formal offer was to be made by the private equity fund, the board of directors would consider, evaluate and recommend a course of action to its shareholders," further added Dr. Arella.
The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
SPPH NEWS!!
Spencer Pharmaceutical Hires Regulatory Affairs Specialist
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.30 +0.02
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Tuesday November 2, 2010, 8:00 am EDT
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has hired the services of Dr. Yves Lachance, a regulatory affair specialist.
Dr. Lachance holds a Ph.D. in physiology and endocrinology from Laval University (Quebec, Canada) and a postdoctoral fellowship at a federal government research laboratory in Lennoxville (Canada). From 1992 to 1996, Dr. Lachance was a research associate at the University Hospital (CHUL) Research Center in Quebec City. He then joined the biopharmaceutical company Aeterna-Zentaris (formerly Aeterna Laboratories) where he held various positions with increasing responsibilities from Associate Director Process Development, to Associate Director Regulatory Affairs and Principal Director Quality Assurance. Since 2008, Dr. Lachance has been an independent consultant in Pharmaceutical development, Regulatory Affairs and Quality Assurance and he has been active as a member of the Canadian Association of Professional Regulatory Affairs (CAPRA), the US Drug Information Association (DIA) and the American Society for Quality (ASQ).
"We are pleased that Dr. Lachance has accepted our offer and will be an active and very valuable part of our team," said Dr. Arella, President of Spencer Pharmaceutical, Inc. "As a consultant to Spencer Pharmaceutical, Dr. Lachance will provide expertise in drug development, regulatory affairs, strategic planning and submissions. He will be an important asset in our goal of achieving high standards of quality in our product development," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
SPPH NEWS!!
Spencer Pharmaceutical Hires Regulatory Affairs Specialist
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.30 +0.02
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Tuesday November 2, 2010, 8:00 am EDT
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has hired the services of Dr. Yves Lachance, a regulatory affair specialist.
Dr. Lachance holds a Ph.D. in physiology and endocrinology from Laval University (Quebec, Canada) and a postdoctoral fellowship at a federal government research laboratory in Lennoxville (Canada). From 1992 to 1996, Dr. Lachance was a research associate at the University Hospital (CHUL) Research Center in Quebec City. He then joined the biopharmaceutical company Aeterna-Zentaris (formerly Aeterna Laboratories) where he held various positions with increasing responsibilities from Associate Director Process Development, to Associate Director Regulatory Affairs and Principal Director Quality Assurance. Since 2008, Dr. Lachance has been an independent consultant in Pharmaceutical development, Regulatory Affairs and Quality Assurance and he has been active as a member of the Canadian Association of Professional Regulatory Affairs (CAPRA), the US Drug Information Association (DIA) and the American Society for Quality (ASQ).
"We are pleased that Dr. Lachance has accepted our offer and will be an active and very valuable part of our team," said Dr. Arella, President of Spencer Pharmaceutical, Inc. "As a consultant to Spencer Pharmaceutical, Dr. Lachance will provide expertise in drug development, regulatory affairs, strategic planning and submissions. He will be an important asset in our goal of achieving high standards of quality in our product development," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
given how many PRs the company has put out recently, i wouldn't doubt that at all
just more reason for it to bounce back tomorrow
got 100k today...as long as company keeps the interest up, we will have good volume
just getting into the swing of things now...SPPH has caught my eye with how many PRs have been put out lately...gimme some good ones to look at
will not be a stranger...back in the game after a little break
i believe we will head back to .30 in an hour...we have some good support there.